Stintzing, S <br/><br/>
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  07 2017 
 - 50-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2017.03.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Camptothecin--administration & dosage<br/>Cetuximab--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Exons--genetics<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Leucovorin--administration & dosage<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Retrospective Studies<br/>Treatment Outcome